Safety and Dosing Guidelines for Nebulized Lidocaine in Endoscopic‑Assisted Nasogastric Tube Placement

Dosing Limits and Toxicity Thresholds

The maximum recommended topical lidocaine dose for adults is 9 mg · kg⁻¹ lean body weight (≈ 630 mg for a 70 kg adult), providing a clear ceiling far above the proposed 100 mg dose【@1】.
Systemic toxicity is observed at plasma concentrations corresponding to 6.0–9.3 mg · kg⁻¹ (≈ 420–650 mg in a typical adult), indicating that a 100 mg dose is well below the toxic range【@1】.

Concentration Recommendations

4 % lidocaine solution is the highest concentration endorsed for adult airway topicalization, balancing efficacy with safety【@4】.
Lower concentrations (1–2 %) are reserved for pediatric patients weighing less than 10 kg, confirming that 4 % is appropriate for adult use【@4】.
Concentrations >4 % must never be used in any patient, as higher concentrations increase toxicity risk without added benefit【@4】.

Procedure‑Specific Advantages

Endoscopic assistance enables direct visualization of anesthetic spread, allowing the clinician to confirm adequate mucosal anesthesia before advancing the NG tube【@1】.
The topical effect of lidocaine persists for 30–60 minutes, providing sufficient time for scope‑assisted NG placement, which is typically faster than blind insertion【@5】.

Safety Monitoring During and After Administration

Early signs of local anesthetic systemic toxicity (LAST) include circumoral numbness, facial tingling, metallic taste, dizziness, and euphoria; detection should prompt immediate cessation of further lidocaine administration【@2】.
Patients should be observed for 30–60 minutes post‑procedure to identify any delayed systemic absorption, although this is unlikely with a 100 mg dose【@2】.
20 % intravenous lipid emulsion must be readily available whenever lidocaine topicalization is performed, serving as the antidote for potential LAST【@2】.

Documentation Requirements

Record the total lidocaine dose (100 mg), concentration (4 %), route (nebulized), and timing in the patient’s chart【@4】.
If additional topical lidocaine is applied (e.g., spray‑as‑you‑go), calculate the cumulative dose and ensure it remains below 9 mg · kg⁻¹【@1】.

Additional Safety Considerations

Avoid lidocaine solutions containing vasoconstrictors (e.g., epinephrine) for airway topicalization, as they raise the risk of hypertensive crises and cardiac arrhythmias【@4】.
After topicalization, keep the patient nil per os (NPO) for at least 1 hour to reduce aspiration risk while pharyngeal sensation returns【@5】.
Ensure recovery staff are trained to recognize signs of aspiration and LAST, even though the likelihood is minimal with the low dose used【@5】.

Comparative Dosing with Awake Intubation Protocols

Awake intubation protocols typically employ 200 mg of 4 % nebulized lidocaine (5 mL) plus additional spray‑as‑you‑go dosing, reaching up to 500 mg total in adults【@1】.
The 100 mg dose for NG tube placement therefore represents ≈ 50 % of the nebulized component and ≈ 20 % of the total dose used for awake intubation, offering a substantial safety margin.

Supporting Evidence for Combined Techniques

Adding a spray‑as‑you‑go technique to nebulized lidocaine provides superior airway anesthesia compared with nebulization alone, supporting the use of combined topicalization when endoscopic visualization is available【@2】.

All bullet points are sourced from peer‑reviewed guidelines or consensus statements; specific strength of evidence was not explicitly stated in the cited references.